{
    "Patient Information": {
        "Patient ID": "6600",
        "Patient Name": "Monica Morales",
        "Date of Birth": "1942-08-20",
        "Age": 82,
        "Gender": "Male",
        "Contact Information": "N/A",
        "Address": "N/A"
    },
    "Diagnosis Information": {
        "Diagnosis Center": "N/A",
        "Doctor Name": "Dr. Samantha Klein",
        "Accession Number": "N/A",
        "Date of Diagnosis": "N/A",
        "Date of Report Issuance": "N/A",
        "CLIA Number": "N/A",
        "Laboratory Medical Director ": "N/A",
        "Method of Analysis": [
            "NGS",
            "Seq",
            "IHC"
        ],
        "Pipeline Version (Report Version)": "N/A"
    },
    "Cancer Information": {
        "Cancer Type": "Lymphoma",
        "Cancer Stage": "Not explicitly stated",
        "Cancer Grade": "Not explicitly stated",
        "Cancer Location in the Body": "Colorectal",
        "Tumor Specimen Source": "Rectum",
        "Tumor Percentage in Sample": "N/A",
        "Normal Specimen Source": "N/A",
        "Date of Tumor Sample Collection": "2023-12-25",
        "Date Tumor Sample Received": "2023-12-25",
        "Date of Normal Sample Collection": "N/A",
        "Date Normal Sample Received": "N/A"
    },
    "Biomarkers": {
        "General Biomarkers": {
            "Microsatellite Instability (MSI)": "Low",
            "Tumor Mutational Burden (TMB)": "13 mutations/Mb High",
            "Tumor Mutational Burden Percentile": "N/A",
            "Loss of Heterozygosity (LOH)": "High - 21% of tested genomic segments exhibit LOH",
            "Mismatch Repair (MMR) Status": "N/A",
            "PDL1 Expression": [
                "Positive| 3+, 50%"
            ],
            "EBV (Epstein-Barr Virus) Status": "N/A",
            "Other Immunotherapy Markers": "N/A",
            "Low-Coverage Regions (Indeterminate Genes)": [
                "RNF43",
                "ALK",
                "DICER1",
                "MYD88",
                "AKT1"
            ]
        },
        "Gene Mutations": [
            {
                "Gene Name": "BRCA1",
                "DNA Mutation Description": "A",
                "Protein Variant": "p.A374E",
                "Mutation Effect": "N/A",
                "Functional Impact": "N/A",
                "Exon Number": 10,
                "Variant Allele Fraction": "36.65",
                "Transcript ID": "N/A",
                "Somatic or Germline": "N/A",
                "Potentially Actionable or Biologically Relevant": "N/A",
                "Analyte": "DNA tumor",
                "Method of Detection ": "Seq",
                "Pathogenicity": "Likely Benign",
                "Pertinent Negative Results": "N/A"
            },
            {
                "Gene Name": "NCSTN",
                "DNA Mutation Description": "c.487T>C",
                "Protein Variant": "p.S163P",
                "Mutation Effect": "N/A",
                "Functional Impact": "N/A",
                "Exon Number": 8,
                "Variant Allele Fraction": "7.83",
                "Transcript ID": "N/A",
                "Somatic or Germline": "N/A",
                "Potentially Actionable or Biologically Relevant": "N/A",
                "Analyte": "DNA tumor",
                "Method of Detection ": "Seq",
                "Pathogenicity": "Likely Benign",
                "Pertinent Negative Results": "N/A"
            },
            {
                "Gene Name": "STAT5B",
                "DNA Mutation Description": "c.1912A>T",
                "Protein Variant": "p.L239R",
                "Mutation Effect": "N/A",
                "Functional Impact": "N/A",
                "Exon Number": 16,
                "Variant Allele Fraction": "21.27",
                "Transcript ID": "N/A",
                "Somatic or Germline": "N/A",
                "Potentially Actionable or Biologically Relevant": "N/A",
                "Analyte": "DNA tumor",
                "Method of Detection ": "Seq",
                "Pathogenicity": "Likely Benign",
                "Pertinent Negative Results": "N/A"
            },
            {
                "Gene Name": "ALK",
                "DNA Mutation Description": "c.416G>A",
                "Protein Variant": "p.R139H",
                "Mutation Effect": "N/A",
                "Functional Impact": "N/A",
                "Exon Number": 9,
                "Variant Allele Fraction": "8.61",
                "Transcript ID": "N/A",
                "Somatic or Germline": "N/A",
                "Potentially Actionable or Biologically Relevant": "N/A",
                "Analyte": "DNA tumor",
                "Method of Detection ": "Seq",
                "Pathogenicity": "Likely Pathogenic",
                "Pertinent Negative Results": "N/A"
            },
            {
                "Gene Name": "SDHA",
                "DNA Mutation Description": "3",
                "Protein Variant": "p.A1515S",
                "Mutation Effect": "N/A",
                "Functional Impact": "N/A",
                "Exon Number": 19,
                "Variant Allele Fraction": "19.33",
                "Transcript ID": "N/A",
                "Somatic or Germline": "N/A",
                "Potentially Actionable or Biologically Relevant": "N/A",
                "Analyte": "DNA tumor",
                "Method of Detection ": "Seq",
                "Pathogenicity": "Pathogenic",
                "Pertinent Negative Results": "N/A"
            },
            {
                "Gene Name": "HBB",
                "DNA Mutation Description": "c.2524G>A",
                "Protein Variant": "p.T862I",
                "Mutation Effect": "N/A",
                "Functional Impact": "N/A",
                "Exon Number": 8,
                "Variant Allele Fraction": "1.54",
                "Transcript ID": "N/A",
                "Somatic or Germline": "N/A",
                "Potentially Actionable or Biologically Relevant": "N/A",
                "Analyte": "DNA tumor",
                "Method of Detection ": "Seq",
                "Pathogenicity": "Benign",
                "Pertinent Negative Results": "N/A"
            },
            {
                "Gene Name": "PTCH1",
                "DNA Mutation Description": "N/A",
                "Protein Variant": "N/A",
                "Mutation Effect": "Fusion not detected",
                "Functional Impact": "N/A",
                "Exon Number": "N/A",
                "Variant Allele Fraction": "N/A",
                "Transcript ID": "N/A",
                "Somatic or Germline": "N/A",
                "Potentially Actionable or Biologically Relevant": "N/A",
                "Analyte": "RNA-Tumor",
                "Method of Detection ": "Seq",
                "Pathogenicity": "N/A",
                "Pertinent Negative Results": "N/A"
            },
            {
                "Gene Name": "PHF6",
                "DNA Mutation Description": "N/A",
                "Protein Variant": "N/A",
                "Mutation Effect": "Fusion not detected",
                "Functional Impact": "N/A",
                "Exon Number": "N/A",
                "Variant Allele Fraction": "N/A",
                "Transcript ID": "N/A",
                "Somatic or Germline": "N/A",
                "Potentially Actionable or Biologically Relevant": "N/A",
                "Analyte": "DNA-Tumor",
                "Method of Detection ": "Seq",
                "Pathogenicity": "N/A",
                "Pertinent Negative Results": "N/A"
            },
            {
                "Gene Name": "ARID2",
                "DNA Mutation Description": "N/A",
                "Protein Variant": "N/A",
                "Mutation Effect": "Fusion not detected",
                "Functional Impact": "N/A",
                "Exon Number": "N/A",
                "Variant Allele Fraction": "N/A",
                "Transcript ID": "N/A",
                "Somatic or Germline": "N/A",
                "Potentially Actionable or Biologically Relevant": "N/A",
                "Analyte": "RNA-Tumor",
                "Method of Detection ": "Seq",
                "Pathogenicity": "N/A",
                "Pertinent Negative Results": "N/A"
            }
        ],
        "Immunochemistry Biomarkers": [
            {
                "Biomarker Name": "ER",
                "Number of Stained Cells": "N/A",
                "Percentage of Expression": "3+, 52%",
                "Interpretation": "Positive"
            },
            {
                "Biomarker Name": "MSH6",
                "Number of Stained Cells": "N/A",
                "Percentage of Expression": "1+, 75%",
                "Interpretation": "Positive"
            },
            {
                "Biomarker Name": "AR",
                "Number of Stained Cells": "N/A",
                "Percentage of Expression": "3+, 91%",
                "Interpretation": "Positive"
            },
            {
                "Biomarker Name": "PMS2",
                "Number of Stained Cells": "N/A",
                "Percentage of Expression": "1+, 93%",
                "Interpretation": "Negative"
            },
            {
                "Biomarker Name": "ERBB2",
                "Number of Stained Cells": "N/A",
                "Percentage of Expression": "2+, 18%",
                "Interpretation": "Negative"
            },
            {
                "Biomarker Name": "PD-L1(SP142)",
                "Number of Stained Cells": "N/A",
                "Percentage of Expression": "1+, 21%",
                "Interpretation": "Positive"
            },
            {
                "Biomarker Name": "PTEN",
                "Number of Stained Cells": "N/A",
                "Percentage of Expression": "2+, 70%",
                "Interpretation": "Negative"
            }
        ]
    },
    "Therapeutic Information": {
        "FDA-Approved Therapies for Current Diagnosis": [
            {
                "Therapy Name": "abemaciclib, palbociclib, ribociclib, endocrine, therapy, everolimus",
                "Therapy Type": "targeted therapy",
                "Evidence Source": "N/A",
                "Associated Biomarker": {
                    "Biomarker Name": "ER",
                    "Biomarker level": "level 2",
                    "Positively/Negatively Associated": "BENEFIT"
                }
            },
            {
                "Therapy Name": "abemaciclib, palbociclib, ribociclib, endocrine therapy",
                "Therapy Type": "targeted therapy",
                "Evidence Source": "N/A",
                "Associated Biomarker": {
                    "Biomarker Name": "PR",
                    "Biomarker level": "level 2",
                    "Positively/Negatively Associated": "BENEFIT"
                }
            },
            {
                "Therapy Name": "pembrolizumab",
                "Therapy Type": "immunotherapy",
                "Evidence Source": "N/A",
                "Associated Biomarker": {
                    "Biomarker Name": "TMB",
                    "Biomarker level": "level 2",
                    "Positively/Negatively Associated": "BENEFIT"
                }
            },
            {
                "Therapy Name": "trastuzumab, ado-trastuzumab emtansine, pertuzumab, fam-trastuzumab deruxtecan-nxki, lapatinib, neratinib, tucatinib",
                "Therapy Type": "targeted therapy",
                "Evidence Source": "N/A",
                "Associated Biomarker": {
                    "Biomarker Name": "ERBB2",
                    "Biomarker level": "level 1",
                    "Positively/Negatively Associated": "LACK OF BENEFT"
                }
            }
        ],
        "FDA-Approved Therapies for Other Indications": []
    },
    "Clinical Trials": [
        {
            "Trial Title": "Anti hormonal therapy",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "N/A",
            "Trial Location": "N/A",
            "Therapy Type": "Chemotherapy",
            "Medication": "anastrazole, letrozole, exemestane, fulvestrant, tamoxifen, goserelin, leuprolide",
            "Associated Mutations": [
                "ER"
            ]
        },
        {
            "Trial Title": "Anti hormonal therapy",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "N/A",
            "Trial Location": "N/A",
            "Therapy Type": "Chemotherapy",
            "Medication": "anastrazole, letrozole, exemestane, fulvestrant, tamoxifen, goserelin, leuprolide",
            "Associated Mutations": [
                "PR"
            ]
        },
        {
            "Trial Title": "Anti inflammatory agents",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "N/A",
            "Trial Location": "N/A",
            "Therapy Type": "Chemotherapy",
            "Medication": "aspirin",
            "Associated Mutations": [
                "PIK3CA"
            ]
        },
        {
            "Trial Title": "Akt inhibitors",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "N/A",
            "Trial Location": "N/A",
            "Therapy Type": "Targeted therapy",
            "Medication": "AZD5363, MK-2206, ipataserib",
            "Associated Mutations": [
                "ARID1A"
            ]
        },
        {
            "Trial Title": "immunomodulatory agents",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "N/A",
            "Trial Location": "N/A",
            "Therapy Type": "Targeted therapy",
            "Medication": "avelumab, atezolizumab, durvalumab, ipilimumab, nivolumab, pembrolizumab",
            "Associated Mutations": [
                "TMB"
            ]
        },
        {
            "Trial Title": "PARP inhibitors",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "N/A",
            "Trial Location": "N/A",
            "Therapy Type": "Targeted therapy",
            "Medication": "BGB-290, BMN-673, olaparib, rucaparib, talazoparib",
            "Associated Mutations": [
                "NBN"
            ]
        },
        {
            "Trial Title": "Akt/mTor inhibitors",
            "Clinical Trial ID": "N/A",
            "Phase of Trial": "N/A",
            "Trial Location": "N/A",
            "Therapy Type": "Targeted therapy",
            "Medication": "AZD5363, BYL719, MK-2206, ipataserib, everolimus, temsirolimus",
            "Associated Mutations": [
                "PIK3CA"
            ]
        }
    ],
    "Variants of Unknown Significance (VUS)": [
        {
            "Gene Name": "HBA2",
            "DNA Alteration": "c",
            "Protein Variant": "p.Y303H",
            "Mutation Effect": "N/A",
            "Variant Allele Fraction": "26.71",
            "Exon Number": 7,
            "Transcript ID": "N/A",
            "Functional Impact": "N/A",
            "Somatic or Germline": "N/A"
        },
        {
            "Gene Name": "IDH1",
            "DNA Alteration": "c.1436G>A",
            "Protein Variant": "p.R479H",
            "Mutation Effect": "N/A",
            "Variant Allele Fraction": "8.83",
            "Exon Number": 15,
            "Transcript ID": "N/A",
            "Functional Impact": "N/A",
            "Somatic or Germline": "N/A"
        },
        {
            "Gene Name": "PAX5",
            "DNA Alteration": "c.1849G>T",
            "Protein Variant": "p.G996R",
            "Mutation Effect": "N/A",
            "Variant Allele Fraction": "10.04",
            "Exon Number": 10,
            "Transcript ID": "N/A",
            "Functional Impact": "N/A",
            "Somatic or Germline": "N/A"
        },
        {
            "Gene Name": "KLF1",
            "DNA Alteration": "c.402C>G",
            "Protein Variant": "p.C134W",
            "Mutation Effect": "N/A",
            "Variant Allele Fraction": "11.55",
            "Exon Number": 6,
            "Transcript ID": "N/A",
            "Functional Impact": "N/A",
            "Somatic or Germline": "N/A"
        }
    ],
    "Additional Indicators": []
}